MARKET

ONCT

ONCT

Oncternal Therapeutics Inc
NASDAQ
9.04
-0.16
-1.74%
Closed 16:00 02/23 EST
OPEN
9.25
PREV CLOSE
9.20
HIGH
9.25
LOW
9.03
VOLUME
3.29K
TURNOVER
0
52 WEEK HIGH
20.80
52 WEEK LOW
5.22
MARKET CAP
26.76M
P/E (TTM)
-0.6299
1D
5D
1M
3M
1Y
5Y
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 4d ago
Weekly Report: what happened at ONCT last week (0212-0216)?
Weekly Report · 6d ago
Zoetis (ZTS) Q4 Earnings Lag Estimates
NASDAQ · 02/13 13:10
Oppenheimer Remains a Hold on Oncternal Therapeutics (ONCT)
TipRanks · 02/13 12:37
Weekly Report: what happened at ONCT last week (0205-0209)?
Weekly Report · 02/12 12:03
Weekly Report: what happened at ONCT last week (0129-0202)?
Weekly Report · 02/05 12:16
American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday
Wells Fargo cut Warner Bros. Discovery, Inc. Price target from $16 to $12. Keybanc raised the price target for Alphabet Inc. (NASDAQ:GOOGL) to $165 on Friday. Barclays boosted the price targets for American Express Company and Dollar General Corporation.
Benzinga · 01/29 12:34
Weekly Report: what happened at ONCT last week (0122-0126)?
Weekly Report · 01/29 11:59
More
About ONCT
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

Webull offers Oncternal Therapeutics Inc stock information, including NASDAQ: ONCT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCT stock methods without spending real money on the virtual paper trading platform.